The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Genomics and Drug Response
Open accessAbstract
harmacogenomics is the study of the role of inherited and acquired genetic variation in drug response.1 Clinically relevant pharmacogenetic examples, mainly involving drug metabolism, have been known for decades, but recently, the field of pharmacogenetics has evolved into "pharmacogenomics," involving a shift from a focus on individual candidate genes to genomewide association studies.Such studies are based on a rapid scan of markers across the genome of persons affected by a particular disorder or drug-response phenotype and persons who are not affected, with tests for association that compare genetic variation in a case-control setting. 2 An example is provided in this issue of the Journal: McCormack and colleagues, testing for genomewide association, identified an HLA allele that is associated with hypersensitivity reactions to the anticonvulsant and mood-stabilizing drug carbamazepine in persons of European descent.3 Pharmacogenomics facilitates the identification of biomarkers that can help physicians optimize drug selection, dose, and treatment duration and avert adverse drug reactions.In addition, pharmacogenomics can provide new insights into mechanisms of drug action and as a result can contribute to the development of new therapeutic agents.In 2003, two reviews of pharmacogenetics were published the Journal.4,5 Since then, both genomic science and its application to drug response have undergone major advances.6 Here we review some of those advances, with an emphasis on discovery through genomewide association studies.We describe examples that highlight principles of pharmacogenomics that are relevant to a wide variety of drugs.The Food and Drug Administration (FDA) has altered drug labels and issued warnings about pharmacogenomic variation affecting drug response, raising the issue of the level of evidence required to show clinical utility 7 and the respective roles of regulatory agencies such as the FDA and of academic and professional societies in the evaluation of pharmacogenetic analyses for the clinic. C a r diova scul a r DrugsMany drugs have proven efficacy in the treatment and prevention of cardiovascular disease.Not uncommonly, these drugs have narrow therapeutic indexes that are influenced by genetic variation -a hallmark of drugs for which pharmacogenomic approaches are likely to provide substantial clinical benefit.The anticoagulant agents warfarin and clopidogrel are high on the list of widely prescribed cardiovascular drugs with narrow therapeutic indexes.The pharmacogenomic features of these drugs illustrate the rapid evolution of our understanding of the role of inheritance in the variation in drug efficacy and the risk of adverse drug reactions.In the case of both agents, the application of classic candidate-gene pharmacogeneticsThe New England
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,514
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.449 · Cited by 2,141
Sabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,835
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Study, F. T. H. C., Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.447 · Cited by 1,826
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Self-citationA marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
Genomewide Association Studies and Assessment of the Risk of Disease
Manolio, T. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905980 · Cited by 1,512
Shuldiner, A. R. (2009) · JAMA · doi:10.1001/jama.2009.1232 · Cited by 1,505
Identification of the platelet ADP receptor targeted by antithrombotic drugs
Hollopeter, G., Jantzen, H.-M., Vincent, D., Li, G., England, L., Ramakrishnan, V., Yang, R.-B., Nurden, P., Nurden, A., Julius, D., et al. (2001) · Nature · doi:10.1038/35051599 · Cited by 1,423
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Self-citationMallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Mega, J. L., Simon, T., Collet, J.-P., Anderson, J. L., Antman, E. M., Bliden, K., Cannon, C. P., Danchin, N., Giusti, B., Gurbel, P., et al. (2010) · JAMA · doi:10.1001/jama.2010.1543 · Cited by 1,135
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H.-J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., et al. (2004) · Nature · doi:10.1038/nature02214 · Cited by 1,134
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Self-citationKing, S. B., Smith, S. C., Hirshfeld, J. W., Jacobs, A. K., Morrison, D. A., Williams, D. O., 2005 WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.188208 · Cited by 1,014
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
study, F. T. D., Daly, A. K., International SAE Consortium, Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.379 · Cited by 944
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperavičiūtė, D., Carrington, M., Sills, G. J., Marson, T., Jia, X., de Bakker, P. I. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013297 · Cited by 925
Wallentin, L., James, S., Storey, R. F., Armstrong, M., Barratt, B. J., Horrow, J., Husted, S., Katus, H., Steg, P. G., Shah, S. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61274-3 · Cited by 799
Identification and Biological Activity of the Active Metabolite of Clopidogrel
Savi, P., Pereillo, J. M., Uzabiaga, M. F., Combalbert, J., Picard, C., Maffrand, J. P., Pascal, M., & Herbert, J. M. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614133 · Cited by 754
Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan
Chen, P., Lin, J.-J., Lu, C.-S., Ong, C.-T., Hsieh, P. F., Yang, C.-C., Tai, C.-T., Wu, S.-L., Lu, C.-H., Hsu, Y.-C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009717 · Cited by 711
Identification of the gene for vitamin K epoxide reductase
Li, T., Chang, C.-Y., Jin, D.-Y., Lin, P.-J., Khvorova, A., & Stafford, D. W. (2004) · Nature · doi:10.1038/nature02254 · Cited by 707
Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci915 · Cited by 686
Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000433 · Cited by 632
Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults
Budnitz, D. S., Shehab, N., Kegler, S. R., & Richards, C. L. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-11-200712040-00006 · Cited by 607
Bleeding Complications With Warfarin Use: A Prevalent Adverse Effect Resulting in Regulatory Action
Wysowski, D. K., Nourjah, P., & Swartz, L. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.13.1414 · Cited by 547
NIH Consensus Statement on Management of Hepatitis C: 2002.
(2002) · PubMed · Cited by 536
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Paré, G., Mehta, S. R., Yusuf, S., Anand, S. S., Connolly, S. J., Hirsh, J., Simonsen, K., Bhatt, D. L., Fox, K. A. A., & Eikelboom, J. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008410 · Cited by 534
Genomic Medicine — An Updated Primer
Feero, W. G., Guttmacher, A. E., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0907175 · Cited by 442
Ferrell, P. B., & McLeod, H. L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.10.1543 · Cited by 439
Self-citationHetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O., Spreen, B., Lafon, S., Pearce, G., & Steel, H. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80132-6 · Cited by 406
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
Holmes, D. R., Dehmer, G. J., Kaul, S., Leifer, D., O’Gara, P. T., & Stein, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.013 · Cited by 354
Warfarin Genotyping Reduces Hospitalization Rates
Epstein, R. S., Moyer, T. P., Aubert, R. E., O'Kane, D. J., Xia, F., Verbrugge, R. R., Gage, B. F., & Teagarden, J. R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.009 · Cited by 336
McDonald, M. G., Rieder, M. J., Nakano, M., Hsia, C. K., & Rettie, A. E. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.054833 · Cited by 320
Collins, F. (2010) · Nature · doi:10.1038/464674a · Cited by 247
Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation
Weinshilboum, R. M., & Wang, L. (2006) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162315 · Cited by 231
Self-citationIngle, J. N., Schaid, D. J., Goss, P. E., Liu, M., Mushiroda, T., Chapman, J.-A. W., Kubo, M., Jenkins, G. D., Batzler, A., Shepherd, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5064 · Cited by 211
Self-citationPharmacogenetics of oral anticoagulants
Daly, A. K., & King, B. P. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00002 · Cited by 195
Multiple personal genomes await
Venter, J. C. (2010) · Nature · doi:10.1038/464676a · Cited by 159
A genome-wide association study of acenocoumarol maintenance dosage
Teichert, M., Eijgelsheim, M., Rivadeneira, F., Uitterlinden, A. G., van Schaik, R. H. N., Albert Hofman, D., Smet, P. A. G. M. D., van Gelder, T., Visser, L. E., & Stricker, B. H. C. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp309 · Cited by 158
Liver damage from flucloxacillin, cloxacillin and dicloxacillin
Olsson, R., Wiholm, B. ‐., Sand, C., Zettergren, L., Hultcrantz, R., & Myrhed, M. (1992) · Journal of Hepatology · doi:10.1016/0168-8278(92)90029-o · Cited by 139
Russmann, S., Kaye, J. A., Jick, S. S., & Jick, H. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02370.x · Cited by 115
Risk factors for development of flucloxacillin associated jaundice.
Fairley, C. K., McNeil, J. J., Desmond, P. V., Smallwood, R. A., Young, H., Forbes, A. B., Purcell, P. M., & Boyd, I. (1993) · BMJ · doi:10.1136/bmj.306.6872.233 · Cited by 91
Assessing the Clinical Utility of Diagnostics Used in Drug Therapy
Woodcock, J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.230 · Cited by 83
Analysis of IL-10, IL-4 and TNF-α polymorphisms in drug-induced liver injury (DILI) and its outcome
Pachkoria, K., Lucena, M. I., Crespo, E., Ruiz‐Cabello, F., López-Ortega, S., Fernández‐Santaella, M. C., Romero‐Gómez, M., Madrazo, A., Durán, J. A., de Dios, A. M., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.03.017 · Cited by 80
Interferon-alfa, interferon-λ and hepatitis C
OʼBrien, T. R. (2009) · Nature Genetics · doi:10.1038/ng.453 · Cited by 76
(2010) · Nature · doi:10.1038/464649a · Cited by 76
Pharmacogenetics of Coumarinic Oral Anticoagulants
Manolopoulos, V. G., Ragia, G., & Tavridou, A. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.31 · Cited by 71
From the Molecule to the Clinic — Inhibiting HER2 to Treat Breast Cancer
Eisenhauer, E. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441110 · Cited by 64
Zambon, C., Pengo, V., Padrini, R., Basso, D., Schiavon, S., Fogar, P., Nisi, A., Frigo, A. C., Moz, S., Pelloso, M., et al. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.162 · Cited by 63
Adjuvant aromatase inhibitor therapy: Outcomes and safety
Janni, W., & Hepp, P. G. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.010 · Cited by 60
Brown, E. G., Wood, L., & Wood, S. (2006) · Wiley eBooks · doi:10.1002/9780470059210 · Cited by 18
Alternatives to Warfarin-The Next Generation of Anticoagulants
Kanagasabapathy, P., Chowdary, P., & Gatt, A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00197.x · Cited by 14
Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer
Freedman, R. A., & Winer, E. P. (2010) · The Breast · doi:10.1016/j.breast.2009.11.009 · Cited by 11
Cited by
A Tale of Coronary Artery Disease and Myocardial Infarction
Nabel, E. G., & Braunwald, E. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1112570 · Cited by 994
Pharmacogenomics in the clinic
Relling, M. V., & Evans, W. E. (2015) · Nature · doi:10.1038/nature15817 · Cited by 904
Implementing genomic medicine in the clinic: the future is here
Manolio, T. A., Chisholm, R. L., Ozenberger, B., Roden, D. M., Williams, M. S., Wilson, R., Bick, D., Bottinger, E. P., Brilliant, M. H., Eng, C., et al. (2013) · Genetics in Medicine · doi:10.1038/gim.2012.157 · Cited by 566
Self-citationNg, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557
Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel, U., Howard, S. C., Hunkler, R. J., Klein, T. E., Evans, W. E., & Relling, M. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124835 · Cited by 511
Metadata
- Authors
- Wang, L., McLeod, H. L., & Weinshilboum, R. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-24
- Volume
- 364
- Issue
- 12
- Pages
- 1144-1153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102316672
- Cited by
- 613
- References
- 69
- FWCI
- 81.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.